Conference Coverage
GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.
Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
Advertisement
The Latest From GI Oncology Now
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.